文献速递其他结缔组织病

「我做得对吗?」医生对系统性硬化症临床试验中整体评估的认知

'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该探索性定性研究访谈了18名风湿科医生和1名患者研究伙伴,探讨他们对医生整体评估(PhyGA)的认知、在随机对照试验中的作用及自身评估方式。识别出医生不确定性、PhyGA实施差异、改善一致性的努力及PhyGA效用四大主题,认为PhyGA虽存在异质性但有助于评估治疗反应。

要点

  • 多数参与者认为PhyGA应评估系统性硬化症可变方面,通常视为疾病活动度。
  • 对评估疾病活动度的最佳方法存在相当不确定性,PhyGA实施存在变异性。
  • 尽管有局限,医生普遍同意PhyGA有用,可评估系统性硬化症不可量化方面。

核心结论

  • 研究识别出系统性硬化症中PhyGA实施方法存在显著异质性,这种变异被视为PhyGA的局限。
  • 总体而言,PhyGA被视为一种有用的工具,可辅助随机对照试验中治疗反应的评估。

研究设计与样本

  • 探索性定性研究,邀请具有系统性硬化症临床评估专长和(或)积极参与系统性硬化症研究的参与者。
  • 共访谈18名风湿科医生和1名患者研究伙伴,访谈转录采用演绎与归纳主题分析法分析。

主要发现

  • 识别出四大主题:医生不确定性、PhyGA实施差异、医生改善PhyGA一致性的努力、PhyGA的效用。
  • 多数参与者认为PhyGA应评估系统性硬化症可变方面,通常视为疾病活动度。
  • 对评估疾病活动度的最佳方法存在相当不确定性,参与者对自身实施PhyGA的方法不确定,并发现工具应用存在变异性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Physician global assessments (PhyGAs) are commonly performed in randomized controlled trials (RCTs) in SSc. However, there is no single PhyGA applied across RCTs. We performed an exploratory qualitative study to explore perceptions of the PhyGA, its role in RCTs and how physicians perform their own assessment. METHODS: Participants with expertise in the clinical assessment and, or actively involved in research on SSc were invited to participate. Participants were asked to define disease constructs of activity, damage, severity, and overall health, and to describe how they perform a PhyGA and their perception of what a PhyGA should assess. Interview transcripts were analysed using deductive and inductive thematic analysis. RESULTS: Eighteen rheumatologists and one patient research partner were interviewed. Four major themes were identified: (i) physician uncertainty; (ii) variation in the conduct of a PhyGA; (iii) physician efforts to improve PhyGA consistency; (iv) utility of a PhyGA. Most participants felt a PhyGA should assess changeable aspects of SSc, commonly conceived of as disease activity. There was considerable uncertainty about the optimal method for assessing disease activity. Participants were uncertain about their own methods of performing a PhyGA, and variability in the application of the instrument was identified. Despite these limitations, physicians generally agreed that the PhyGA is useful and can assess unquantifiable aspects of SSc. CONCLUSION: We identified significant heterogeneity in the approach to PhyGAs in SSc. This variation was considered a limitation of the PhyGA. Overall, a PhyGA was viewed as a useful instrument that can aid the assessment of treatment response in RCTs.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sabanovic H, Pauling JD, Baron M, et al. 'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis. Rheumatology (Oxford). 2025. PMID: 40644620. doi:10.1093/rheumatology/keaf377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。